Loading clinical trials...
Loading clinical trials...
Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma
Conditions
Interventions
Pembrolizumab
Taxol
+1 more
Locations
4
United States
USC Keck School of Medicine, Norris Cancer Center
Los Angeles, California, United States
University of Michigan
Ann Arbor, Michigan, United States
Weill Cornell Medicine
New York, New York, United States
Rhode Island Hospital
Providence, Rhode Island, United States
Start Date
March 7, 2017
Primary Completion Date
February 10, 2021
Completion Date
March 1, 2026
Last Updated
March 17, 2026
NCT06340711
NCT05745857
NCT05733689
NCT04900818
NCT07282912
NCT05677490
Lead Sponsor
Weill Medical College of Cornell University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions